Realistic Ways to Enter the Atherectomy Devices Market

Nobody starting from zero should write a plan that competes head-on with Abbott, Boston Scientific, Medtronic, Philips or Cardiovascular Systems Inc. (CSI), five companies that together control roughly 82% of global share. That doesn't mean the category is closed to new entrants; it means the entry point has to be deliberately narrow. Three paths show up repeatedly in plans we've helped structure for this space:

• Single-SKU device company: one peripheral atherectomy catheter, cleared through 510(k), sold into ambulatory surgical centres and office-based labs the majors under-serve.
• Contract manufacturing / private label: building catheter-based devices under an existing OEM's regulatory clearance, which sidesteps the multi-year clinical burden entirely.
• Specialty distribution: becoming the regional distributor or field-service partner for an established manufacturer's console-and-disposable system, which needs far less capital than building a device from scratch.

Each path has a different capital profile, a different regulatory burden, and a different timeline to first revenue. A business plan that names which of the three you're pursuing, and why, reads as credible to a lender or investor in a way that a generic "we will manufacture atherectomy devices" plan never will.

The buyer side of this market is narrower than most physical-product categories, which actually makes the customer-analysis section of the plan easier to write with precision rather than harder. There are, in practice, three buying groups worth separating out: hospital-based interventional cardiology and vascular surgery departments, which move slowly through value-analysis committees but offer the highest procedure volume and the least reimbursement controversy; ambulatory surgical centres, which sit between hospital procurement discipline and office-based-lab speed; and office-based labs, which convert fastest on a per-account basis but carry the reimbursement and appropriate-use scrutiny discussed later on this page. A plan that identifies which of these three segments the business will target first, and explicitly why the other two are being deprioritised in year one, reads as far more credible to a lender than a plan claiming to serve "the healthcare market."

For an investor pitch specifically, the strongest framing we've seen work is a single sentence that names the entry path, the buyer segment, and the specific incumbent weakness being exploited: for example, "[Company] will bring a single-SKU peripheral orbital atherectomy catheter to hospital-based vascular labs by 510(k) clearance in month 12, targeting the reliability gap exposed by [incumbent]'s recent Class I recall." Filling in that template with your own specifics forces the same discipline a full plan requires, before you've written a single financial projection.

Month-by-Month Launch Timeline (Single-SKU 510(k) Route)

• Months 1-3: Design freeze, predicate device selection, and pre-submission (Q-Sub) meeting request with FDA/CDRH.
• Months 3-7: Bench performance testing, biocompatibility testing (ISO 10993 panel), and sterility validation.
• Months 6-9: ISO 13485:2016 QMS implementation running in parallel with testing, since most contract manufacturers require it before they'll quote production.
• Months 8-10: 510(k) submission filed; FDA's target review clock is 90 days, though most first submissions receive at least one Additional Information request that extends this.
• Months 10-14: Clearance received, first production run qualified, field clinical specialists hired ahead of launch.
• Months 14-18: Limited commercial launch into 3-6 accounts, physician training programme, and first reorder cycle to validate the disposable pull-through assumption in the financial model.

What It Actually Costs to Launch an Atherectomy Devices Business

Building even a single-SKU peripheral atherectomy device typically requires $150,000 to $750,000 in the US (£120,000 to £600,000 in the UK) before the first commercial unit ships. This is materially higher than most physical-product business plans because the regulatory and testing burden is fixed regardless of how small the company is, a two-person startup and a 500-person device company both need biocompatibility data and a functioning quality system before FDA will clear a submission.

Cost Breakdown

• Design, prototyping & pre-clinical testing: $40,000-$180,000 (£32K-£145K)
• 510(k) regulatory consulting + FDA user fee: $50,000-$250,000+, including the FY2026 small-business 510(k) fee of $6,517 (£40K-£200K)
• ISO 13485 QMS build-out & contract manufacturing setup: $30,000-$120,000 (£24K-£95K)
• Biocompatibility, sterility & bench performance testing: $20,000-$150,000 (£16K-£120K)
• Product liability & clinical trial insurance: $10,000-$40,000/yr (£8K-£32K/yr)
• Working capital (12 months, pre-revenue): $25,000-$100,000 (£20K-£80K)

For context on scale: independent analysis of 50 devices that successfully navigated the full 510(k) pathway found a median all-in cost of $3.1 million, and broader device-development cost bands run from roughly $2 million to $30 million for a Class II product once you include clinical support and commercialisation (Complizen, 2025). The $150K-$750K range above is the realistic floor for a narrowly scoped single-SKU launch using an existing predicate device and a contract manufacturer, not a full ground-up device programme with in-house clinical trials.

Most first-time plans underestimate this budget by 40-60%, and the shortfall almost always lands in the same three places: an unbudgeted second round of biocompatibility testing after an initial panel comes back inconclusive, an FDA Additional Information request that requires new bench data rather than a paperwork response, and field clinical specialist salaries that get modelled as a post-launch expense when they actually need to start three to four months before first commercial shipment so physicians are trained and confident before the first case. Building a 15-20% contingency line into the regulatory and testing budget, rather than treating contingency as an afterthought in the appendix, is one of the fastest ways to make a device business plan look like it was written by someone who has actually done this before.

Funding Routes

Because atherectomy devices sit in a regulated, capital-intensive category, most first-time founders combine sources rather than relying on one. In the US, SBA 7(a) loans can fund working capital and equipment once a device has cleared FDA review (lenders are reluctant to fund pre-clearance), while early-stage equity or strategic angel investment typically covers the regulatory and testing spend itself. In the UK, the Start Up Loans scheme (up to £25,000 at 6% fixed) rarely covers the full cost alone for a device business, but is frequently layered alongside Innovate UK grants or private angel investment focused on medtech. Our bespoke business plan service builds the funding narrative and financial model lenders and investors expect to see for a regulated device company, see our bespoke business plan service for details.

Contract Manufacturers & Component Suppliers to Know

Almost no first-time atherectomy device company builds its own catheter extrusion, coating, and assembly line from scratch, the capital cost doesn't make sense until volume is proven. Instead, plans in this category typically name a contract manufacturing partner and build the relationship into the operations section. The contract manufacturing market for catheter-based devices ranges from large EMS groups with dozens of ISO 13485-certified sites down to specialised mid-size shops that focus specifically on catheters and delivery systems.

• Prevailing Medical, specialist contract manufacturer for complex catheter development and production.
• Medical Murray, ISO 13485:2016-certified, FDA-registered manufacturer focused on Class III catheters including IVUS and OCT delivery systems.
• Duke Empirical, specialises in novel access catheters and therapeutic/diagnostic delivery systems.
• Jabil Healthcare, large-scale EMS manufacturer with roughly 35 ISO 13485-certified plants across 12 countries, suited to higher-volume production once a device scales.
• Flex Health Solutions, global contract manufacturer with 21 dedicated medical device sites.

When evaluating a contract manufacturer, the plan should specify minimum order quantities, tooling lead times, and whether the manufacturer already holds a Design History File relationship with a predicate device, this last point can shave months off a 510(k) submission because it de-risks the substantial-equivalence argument FDA reviewers are evaluating.

Regulatory Pathways: FDA, MHRA & EU MDR

Regulatory classification is the single biggest variable in an atherectomy devices business plan, and it depends entirely on where in the body the device is used.

United States

• Peripheral vascular atherectomy devices are generally Class II and follow the 510(k) premarket notification pathway through FDA/CDRH.
• Coronary atherectomy devices are Class III due to the higher-risk anatomical location and require a full Premarket Approval (PMA) application with clinical trial data (RegDesk, FDA Final Guidance on Atherectomy Devices).
• FDA released specific draft guidance covering all four atherectomy modalities, directional, rotational, orbital and laser, detailing predicate comparisons, biocompatibility, sterility, and performance testing expectations (MedTech Dive).
• The FY2026 510(k) small-business fee is $6,517; the standard premarket application base fee for FY2026 is $455,000 (relevant primarily to PMA submissions) (Federal Register, FY2026 MDUFA Fees).
• ISO 13485:2016 quality management system certification is a practical prerequisite most contract manufacturers require before they'll take on production.

United Kingdom

• Every medical device must be registered with the MHRA via the Device Online Registration System (DORS) before it can be placed on the Great Britain market.
• Most atherectomy catheters fall into Class IIa or IIb, which requires conformity assessment by a UK-Approved Body before a UKCA mark can be affixed.
• The UK-Approved Body audits the manufacturer's quality management system and reviews technical documentation before issuing a UKCA certificate of conformity (TÜV SÜD, UKCA for Medical Devices).

European Union

Placing an atherectomy device on the EU market requires CE marking under the EU Medical Device Regulation (MDR 2017/745) via a Notified Body. This is generally the most demanding of the three regimes for a Class IIb device, requiring a formal clinical evaluation report and a documented post-market surveillance plan, plan for this to run in parallel with, not after, the US 510(k) process if EU market entry is part of year one or two of the plan.

Pricing, Margins & Unit Economics

Atherectomy devices businesses generally sell into one of two pricing structures, and most plans need both modelled side by side. Single-use catheters wholesale between $1,200 and $3,500 per unit depending on modality, directional, rotational, orbital, or laser. Capital equipment such as generators or consoles ranges from $25,000 to $120,000, but is frequently placed with hospitals and outpatient labs at low or no upfront margin under a razor/razor-blade model, because the real revenue is in the recurring disposable.

Worked Example

A single-SKU peripheral atherectomy device company selling 900 catheters per year at an average net price of $1,850 generates approximately $1,665,000 in annual disposable revenue. At a 62% gross margin, that's roughly $1,032,300 in gross profit. After regulatory affairs headcount, field clinical specialists supporting physician training, quality systems maintenance, and distribution costs, typically 45-55% of gross profit at this early stage, realistic year-two net margin lands in the 5-11% band, which is why the hero stat on this page is deliberately lower than the eye-catching gross margins vendors quote in investor decks.

Additional revenue can come from physician training and certification programmes, extended service contracts on consoles, and, once a second SKU exists, a bundled contract that locks in a hospital system's atherectomy spend across modalities.

The financial model should also separate gross margin by channel, not just by product. A unit sold into a hospital value-analysis-committee contract typically clears at a lower net price but a more predictable multi-year volume commitment, while a unit sold into an individual office-based lab often carries a higher list price but far more volatile month-to-month ordering, since a single physician's caseload can swing a small account's volume by 30-40% quarter to quarter. A plan that blends both channels into one average selling price will understate the working-capital volatility a lender or investor should be underwriting for.

Market Size & Where Demand Is Growing

The global atherectomy devices market was valued at approximately $866.4 million in 2025 and is projected to reach $941 million in 2026 (Global Market Insights). A separate estimate puts the market at $976.00 million in 2024, growing to $1,621.35 million by 2032 at a 6.55% CAGR (Fortune Business Insights). The spread between estimates reflects differing definitions of what counts as "atherectomy" across coronary and peripheral applications, a plan should pick one source and stay consistent with it rather than blending figures from different methodologies.

The demand driver behind the market is straightforward: The SAGE Group's 2025 research found that peripheral artery disease now affects more than 22 million people in the US, a figure well above the 8-12 million commonly cited historically, because older estimates were based on 1995-era population data (The SAGE Group, 2025). Roughly 70% of PAD cases trace back to modifiable risk factors, smoking, obesity, diabetes, hypertension, and hyperlipidemia, which means the addressable patient pool is still expanding as populations age, not shrinking as treatment improves.

Named competitors dominating the current market include Boston Scientific, whose Jetstream rotational atherectomy system targets complex, calcified peripheral lesions; Philips, with its Phoenix atherectomy system; and Avinger, which completed the full commercial launch of its Pantheris LV image-guided directional atherectomy system in August 2024. A credible plan positions a new entrant against this specific competitive set rather than describing "the market" in the abstract, naming who you are actually taking share from, and why, is what separates an investable plan from a generic one.

Geographically, North America remains the largest single market by revenue, driven by the PAD prevalence data above and by the concentration of office-based labs and ambulatory surgical centres that don't exist at the same density in most other healthcare systems. Growth in Asia Pacific and parts of Europe is being driven less by procedure volume today and more by rising diagnosis rates as vascular screening programmes expand, a distinction worth making explicit in a plan's market-sizing section, since a market that is growing because more disease is being found behaves differently, commercially, than one growing because procedure volume per patient is rising.

More Questions Buyers and Investors Ask

What is atherectomy and how does it work?

Atherectomy is a minimally invasive technique that physically removes plaque from inside an artery, rather than compressing it against the artery wall the way balloon angioplasty does. A catheter is inserted through a small incision, typically near the groin or wrist, and guided using imaging to the site of the blockage, where a cutting, grinding, or laser mechanism removes the plaque directly.

What is the difference between directional, rotational, orbital and laser atherectomy?

Directional atherectomy uses a small rotating blade to shave plaque from artery walls, and works well on larger deposits. Orbital and rotational atherectomy use a burr that spins at high speed to grind through hard, heavily calcified plaque, particularly in smaller vessels. Laser atherectomy uses pulsed light energy to ablate plaque, which is often preferred for long or diffuse lesions where mechanical cutting devices are less effective.

Is a coronary atherectomy device Class II or Class III?

Coronary atherectomy devices are Class III because of the higher clinical risk associated with the coronary anatomy, and require a full PMA submission with clinical trial data. Peripheral vascular atherectomy devices are generally Class II and follow the faster 510(k) pathway, this distinction should be one of the first things a business plan states explicitly, since it changes the entire capital and timeline picture.

How is atherectomy reimbursed, and does site of care matter?

Reimbursement depends heavily on which vessel is treated and where the procedure happens. Tibial or peroneal atherectomy with angioplasty is billed under CPT code 37288, iliac artery atherectomy under 0238T (with an ASC Medicare rate of roughly $11,532), and stent-plus-atherectomy combinations under 37235 (MDClarity, CPT Code 37235). A business plan for a device or distribution company should model both hospital outpatient and ambulatory-surgical-centre/office-based-lab reimbursement separately, because rates and site-of-care incentives differ meaningfully between the two settings.

Reimbursement Incentives, Office-Based Labs & Regulatory Scrutiny

No atherectomy devices business plan is complete without addressing the site-of-care shift that has defined this category over the past decade, because it shapes both the commercial opportunity and the compliance risk a new entrant inherits. More than 80,000 atherectomies were billed to Medicare in 2021 for office-based procedures alone, an increase of roughly 60,000 since 2011, and roughly 75% of office-based-lab PAD procedures now involve an atherectomy (Citeline MedTech Insight, HHS OIG watchdog report).

That growth has drawn direct regulatory attention. An HHS Office of Inspector General review flagged roughly $105 million in potentially unnecessary Medicare billing tied to atherectomy overuse, and independent reporting has documented amputation rates as high as 8% among claudication patients in markets where atherectomy use is disproportionately high relative to anatomical need (ProPublica, vascular procedure investigation). A plan selling into this channel should explicitly address how the business will avoid contributing to inappropriate-use patterns, through physician training standards, appropriate-use criteria alignment, or simply by targeting hospital-based accounts rather than the highest-volume office-based labs, because payers and regulators are actively narrowing reimbursement policy in response to this data.

Device reliability is the other side of this scrutiny. The FDA issued a Class I recall (its most serious category) on an atherectomy device sold by Bard Peripheral Vascular, a Becton Dickinson subsidiary, after 163 complaints and 55 injuries related to catheter tip breakage during use, including arterial dissection and rupture risk (Cardiovascular Business, FDA Class I recall coverage). Medtronic's Rotarex system has faced a similar recall pattern tied to patient deaths and injuries (Healthcare Brew). For a new entrant, this cuts both ways: it is a real cautionary note on design and testing rigor, but it is also evidence that incumbent devices have known failure modes a better-engineered product can specifically target and improve on in its own 510(k) substantial-equivalence argument.

Comparing the Three Realistic Entry Strategies

The three entry paths introduced earlier trade off capital intensity, timeline, and control very differently. Laying them out side by side is one of the fastest ways to show a lender or investor that the plan has actually weighed the alternatives rather than defaulting to the most ambitious option.

Most first-time founders underestimate how much the distribution path can teach them about the market before committing capital to a device programme, several Avvale clients in adjacent device categories have deliberately run a distribution business for 12-18 months specifically to build the account relationships and clinical evidence base that then made their eventual 510(k) submission faster and cheaper.

Glossary of Key Terms for This Business Plan

Investors and lenders reviewing a device business plan will expect these terms to be used precisely, not loosely. A short glossary near the back of the plan (or referenced early, as here) signals that the founder understands the regulatory and clinical vocabulary rather than approximating it.

• Predicate device: An already-legally-marketed device that a new 510(k) submission claims substantial equivalence to; choosing the right predicate is the single most important early regulatory decision.
• Substantial equivalence: The FDA standard a 510(k) submission must meet, showing the new device is at least as safe and effective as its predicate, not necessarily identical to it.
• Design History File (DHF): The compiled record of a device's design and development process, required under FDA design controls and typically held or co-owned with a contract manufacturer.
• ISO 13493 vs ISO 13485: Only ISO 13485:2016 is the recognised quality management system standard for medical devices; there is no ISO 13493 standard, and vendors should be evaluated against the correct certification.
• Q-Sub (Pre-Submission) meeting: An optional, non-binding meeting with FDA/CDRH before a formal 510(k) filing, used to validate testing strategy and predicate selection before committing to full submission costs.
• Office-based lab (OBL): A physician-owned outpatient facility, distinct from a hospital or ambulatory surgical centre, where a large and controversial share of atherectomy procedures now take place.
• Razor/razor-blade model: A commercial structure where capital equipment (the console or generator) is placed at low or no margin in exchange for a committed volume of higher-margin disposables.
• Appropriate-use criteria (AUC): Clinical guidelines defining when a procedure like atherectomy is indicated based on lesion characteristics, used by payers and specialty societies to curb overuse.

Sample Business Plan Preview

Here's an extract from the kind of executive summary our team writes for an atherectomy devices business:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for a regulated medical device business:

• Executive Summary, Your device, entry strategy, and funding ask stated in the first page
• Company Overview, Legal structure, IP position, and founding team credentials
• Industry Analysis, Market size, PAD/CAD prevalence trends, and competitive concentration
• Regulatory Strategy, 510(k) vs PMA pathway selection, predicate device analysis, and MHRA/UKCA/EU MDR requirements
• Customer Analysis, Target accounts (hospitals, ASCs, office-based labs) and physician adoption drivers
• Competitor Analysis, Named competitive mapping against Abbott, Boston Scientific, Medtronic, Philips and CSI
• Operations Plan, Contract manufacturing relationships, quality systems, and supply chain
• Management Team, Founder bios, regulatory advisors, and clinical advisory board

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and the regulatory milestone spend schedule lenders expect to see for a device company. See our market research and content service for the research-heavy version of this build.

Frequently Asked Questions

Related Resources

• Building a related device concept? See our heart pump device business plan template for another catheter-adjacent regulatory pathway.
• Comparing entry into diagnostics instead? Our angiography devices business plan template covers the imaging side of the same vascular labs you'd be selling into.
• Not sure which package fits? Start with the free business plan template hub to see every format side by side.
• Want a professional writer instead of a DIY template? Talk to our business plan writer team about regulated medical device plans specifically.